Identifying FDA-Approved Drugs that Upregulate Utrophin A as a Therapeutic Strategy for Duchenne Muscular Dystrophy
- 19 November 2022
- book chapter
- Published by Springer Nature
- Vol. 2587, 495-510
Abstract
Duchenne muscular dystrophy (DMD) is a neuromuscular disease caused by mutations and deletions within the DMD gene, which result in a lack of dystrophin protein at the sarcolemma of skeletal muscle fibers. The absence of dystrophin fragilizes the sarcolemma and compromises its integrity during cycles of muscle contraction, which, progressively, leads to reductions in muscle mass and function. DMD is thus a progressive muscle-wasting disease that results in a loss of ambulation, cardiomyopathy, respiratory impairment, and death. Although there is presently no cure for DMD, recent advances have led to many promising treatments. One such approach entails increasing expression of a homologous protein to dystrophin, named utrophin A, which is endogenously expressed in both healthy and DMD muscle fibers. Upregulation of utrophin A all along the sarcolemma of DMD muscle fibers can, in part, compensate for the absence of dystrophin. Over the years, our laboratory has focused a significant portion of our efforts in identifying and characterizing drugs and small molecules for their ability to target utrophin A and cause its overexpression. As part of these efforts, we have recently developed a novel ELISA-based high-throughput drug screen, to identify FDA-approved drugs that increase the expression of utrophin A in muscle cells in culture as well as in dystrophic mice. Here, we describe our overall strategy to identify and characterize several FDA-approved drugs that upregulate utrophin A expression and provide details on all experimental approaches. Such strategy has the potential to lead to the rapid development of novel therapeutics for DMD. Key words Duchenne muscular dystrophy FDA-approved drugs Disease Utrophin Muscle Drug screen ELISAKeywords
This publication has 36 references indexed in Scilit:
- How to calculate sample size in animal studies?Journal of Pharmacology and Pharmacotherapeutics, 2013
- Arginine butyrate: a therapeutic candidate for Duchenne muscular dystrophyThe FASEB Journal, 2013
- Metabolic remodeling agents show beneficial effects in the dystrophin- deficient mdx mouse modelSkeletal Muscle, 2012
- Daily Treatment with SMTC1100, a Novel Small Molecule Utrophin Upregulator, Dramatically Reduces the Dystrophic Symptoms in the mdx MousePLOS ONE, 2011
- Therapeutic approaches to muscular dystrophyHuman Molecular Genetics, 2011
- Mammalian Models of Duchenne Muscular Dystrophy: Pathological Characteristics and Therapeutic ApplicationsBioMed Research International, 2011
- Differential Expression of Utrophin‐A and ‐B Promoters in the Central Nervous System (CNS) of Normal and Dystrophic mdx MiceBrain Pathology, 2010
- Microutrophin Delivery Through rAAV6 Increases Lifespan and Improves Muscle Function in Dystrophic Dystrophin/Utrophin-deficient MiceMolecular Therapy, 2008
- Systemic Microdystrophin Gene Delivery Improves Skeletal Muscle Structure and Function in Old Dystrophic mdx MiceMolecular Therapy, 2008
- A- and B-utrophin Have Different Expression Patterns and Are Differentially Up-regulated in mdx MuscleJournal of Biological Chemistry, 2002